443

BARIATRIC SURGERY DECREASES THE RISK OF DEVELOPING CANCER: A MUTLICENTER POPULATION-BASED STUDY

Date
May 7, 2023
Explore related products in the following collection:

Loading...

Tracks

Related Products

Thumbnail for 10 YEAR OUTCOMES OF SMOKING CESSATION ATTEMPTS IN REDUCING LOW BONE DENSITY DISEASE IN CHRONIC PANCREATITIS
10 YEAR OUTCOMES OF SMOKING CESSATION ATTEMPTS IN REDUCING LOW BONE DENSITY DISEASE IN CHRONIC PANCREATITIS
BACKGROUND Chronic pancreatitis (CP) may severely impact quality of life (QoL). Since CP is a chronic condition, multiple assessments of QoL are required to obtain a thorough understanding of its impact on patients. Such studies are currently lacking…
Thumbnail for INCIDENCE PROPORTION OF PANCREATIC COMPLICATIONS WITH INCRETIN-BASED THERAPIES: A MULTICENTER POPULATION-BASED STUDY
INCIDENCE PROPORTION OF PANCREATIC COMPLICATIONS WITH INCRETIN-BASED THERAPIES: A MULTICENTER POPULATION-BASED STUDY
Background: Transoral outlet reduction endoscopy (TORe) has been shown to be effective in managing weight regain after Roux-en-Y gastric bypass (RYGB), as has the glucagon-like peptide-1 agonist, liraglutide. However, the effect of adjunctive liraglutide after TORe has yet to be assessed…
Thumbnail for OPEN-CAPSULE PROTON PUMP INHIBITOR IS ASSOCIATED WITH FASTER HEALING TIME FOR MARGINAL ULCERATION AFTER ROUX-EN-Y GASTRIC BYPASS
OPEN-CAPSULE PROTON PUMP INHIBITOR IS ASSOCIATED WITH FASTER HEALING TIME FOR MARGINAL ULCERATION AFTER ROUX-EN-Y GASTRIC BYPASS
BACKGROUND: Despite the advances in the multidisciplinary treatment of gastric adenocarcinoma, the overall 5-year survival remains only 33.3% in North America. R0 resection with adequate lymphadenectomy remains the mainstay therapy…
Thumbnail for BARIATRIC SURGERY IS ASSOCIATED WITH REDUCED RISK OF PANCREATIC CANCER: ANALYSIS OFA U.S. NATIONAL DATABASE
BARIATRIC SURGERY IS ASSOCIATED WITH REDUCED RISK OF PANCREATIC CANCER: ANALYSIS OFA U.S. NATIONAL DATABASE
BACKGROUND: Despite the advances in the multidisciplinary treatment of gastric adenocarcinoma, the overall 5-year survival remains only 33.3% in North America. R0 resection with adequate lymphadenectomy remains the mainstay therapy…